Radiomics in (18)F-FDG PET/CT predicts HER2 status in breast cancer with equivocal immunohistochemistry. Malhaire C. Eur J Radiol 2023;170:111238.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Malhaire C. Radiomics in (18)F-FDG PET/CT predicts HER2 status in breast cancer with equivocal immunohistochemistry. Eur J Radiol 2023;170:111238.
PMID: 38043379